大黄䗪虫胶囊联合恩替卡韦治疗乙肝肝硬化患者的效果  

Effects of Dahuang Zhechong capsules combined with Entecavir in treatment of patients with hepatitis B cirrhosis

作　　者：刘玉章 李艳翠[2] 宋琳琳[3] 时慧[2] LIU Yuzhang;LI Yancui;SONG Linlin;SHI Hui(Department of Pharmacy of the Central Hospital of Jiamusi City,Jiamusi 154002 Heilongjiang,China;Department of Pharmacy of the First Affiliated Hospital of Jiamusi University,Jiamusi 154002 Heilongjiang,China;College of Pharmacy of Jiamusi University,Jiamusi 154002 Heilongjiang,China)

机构地区：[1]佳木斯市中心医院药剂科,黑龙江佳木斯154002 [2]佳木斯大学附属第一医院药学部,黑龙江佳木斯154002 [3]佳木斯大学药学院,黑龙江佳木斯154002

出　　处：《中国民康医学》2023年第18期115-118,共4页Medical Journal of Chinese People’s Health

基　　金：黑龙江省省属本科高校基本科研业务费科研项目资助(2018-KYYWF-0965)。

摘　　要：目的:观察大黄䗪虫胶囊联合恩替卡韦治疗乙型病毒性肝炎(乙肝)肝硬化患者的效果。方法:选取2021年1月至2022年1月佳木斯市中心医院收治的80例乙肝肝硬化患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各40例。对照组予以恩替卡韦治疗,观察组在对照组基础上联合大黄䗪虫胶囊治疗,两组均治疗12个月,比较两组治疗前后肝功能指标[天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)]水平、肝纤维化指标[透明质酸(HA)、层粘连蛋白(LN)、IV型胶原(Col-IV)、Ⅲ型前胶原(PCⅢ)]水平、治疗前后T细胞亚群水平、HBV-DNA水平和HBeAg转阴率。结果:治疗后,两组AST、ALT、TBIL水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组HA、LN、Col-IV、PCⅢ水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于治疗前,且观察组高于对照组,两组CD8^(+)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组HBV-DNA水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组HBeAg转阴率为32.50%,高于对照组的2.50%,差异有统计学意义(P<0.05)。结论:大黄䗪虫胶囊联合恩替卡韦治疗乙肝肝硬化患者可提高HBeAg转阴率,改善T细胞亚群水平,降低肝功能指标水平、肝纤维化指标水平和HBV-DNA水平,效果优于单纯恩替卡韦治疗。Objective:To observe effects of Dahuang Zhechong capsules combined with Entecavir in treatment of patients with hepatitis B cirrhosis.Methods:A prospective study was conducted on 80 patients with hepatitis B cirrhosis admitted to the central hospital of Jiamusi city from January 2021 to January 2022.According to the random number table method,they were divided into control group and observation group,40 cases in each group.The control group was treated with Entecavir,while the observation group was treated with Dahuang Zhechong capsules on the basis of that of the control group.Both groups were treated for 12 months.The levels of liver function indexes[aspartate aminotransferase(AST),alanine aminotransferase(ALT),total bilirubin(TBIL)],liver fibrosis indexes[hyaluronic acid(HA),laminin(LN),type IV collagen(Col-IV),type III procollagen(PCIII)],T cell subsets,and HBV-DNA,and the HBeAg negative rate were compared between the two groups before and after the treatment.Results:After the treatment,the levels of AST,ALT and TBIL in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of HA,LN,Col-IV and PCIII in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of CD8^(+)in the two groups were lower than those before the treatment,and the observation group was lower than the control group;the difference was statistically significant(P<0.05).The levels of HBV-DNA in the two groups were lower than those before the treatment,that in the observation group was lower than that in the control group,and the differences were statistically significan

关 键 词：乙型病毒性肝炎 肝硬化 大黄䗪虫胶囊 肝功能 肝纤维化 免疫功能 

分 类 号：R512.62[医药卫生—内科学]